This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Career Center   |   Print Page   |   Contact Us   |   Sign In   |   Join SRNT
2019 Awards
Share |



SRNT's annual awards presentation will be Friday, February 22, at 1:00 p.m. - 1:30 p.m. in the Grand Ballroom B (Grand Ballroom Level). Our awards are named after pioneers in the field of nicotine and tobacco research, and we are pleased to remember those pioneers. 



The John Slade Award honors individuals who have made outstanding contributions to public health and tobacco control through science-based public policy and public advocacy.

2019 Award Recipient:

Geoffrey T. Fong, Ph.D., FRSC, FCAHS

Professor of Psychology and Public Health and Health Systems,
University of Waterloo;
Senior Investigator, Ontario Institute for Cancer Research;
Principal Investigator, International Tobacco Control Policy Evaluation Project (ITC Project)
Waterloo, Ontario


Dr. John Slade was an expert on the treatment of alcohol, tobacco, and drug addiction and one of America's pioneer advocates for tobacco control.

He was a member of the team that conducted the first scholarly analysis of previously secret documents from the Brown and Williamson Tobacco Company, which formed the basis for the film “The Insider.”  John's analysis led to a landmark series of articles in the Journal of the American Medical Association in 1995, as well as a book, “The Cigarette Papers.” His groundbreaking research to prove that cigarettes are nicotine delivery devices helped make it possible for the Food and Drug Administration to claim regulatory authority over tobacco products under then-FDA Commissioner Dr. David Kessler.

John was appointed Professor of Medicine, Robert Wood Johnson Medical School of the UMDNJ, in 1998. He emerged as a leader in substance abuse prevention and tobacco control for the state of New Jersey through his teaching and clinical work as well as through his active involvement with the Medical Society of New Jersey and the New Jersey Public Health Association. John played a major role in helping New Jersey develop its tobacco prevention and treatment program, funded as part of the 1998 $206 billion settlement with tobacco companies.

He co-edited the first major clinical textbook on nicotine addiction and founded the Committee on Nicotine Dependence of the American Society of Addiction Medicine (ASAM).




Robyn Wootton, PhD

Research Associate in Genetic Epidemiology
Tobacco and Alcohol Research Group, School of Psychological Science, University of Bristol and the MRC Integrative Epidemiology Unit
University of Bristol, Bristol, United Kingdom 

Hongchao Guo, Ph.D

Stanford Cardiovascular Institute
Palo Alto, CA, USA


Ilze Bogdanovica, MSc, MSc, PhD

Senior Research Fellow/ Cancer Research UK Career Development Fellow
Division of Epidemiology and Public Health,
University of Nottingham & UK Centre for Tobacco and Alcohol Studies
England, UK



Krysten W. Bold, Ph.D.

Associate Research Scientist
Yale School of Medicine, Department of Psychiatry
New Haven, CT, USA





The Jarvik-Russell Young Investigator Award, named after Murray Jarvik and Michael Russell, recognizes scientists early in their careers who have made extraordinary contributions to the field of nicotine and tobacco research.

2019 Award Recipient:

Kelvin Choi, PhD, MPH

National Institute on Minority Health and Health Disparities, Division of Intramural Research, National Institutes of Health
Bethesda, Maryland, USA


Dr. Murray Jarvik was born in New York City in 1923. Following medical school, Murray worked at the Yerkes Laboratory in Florida. It was here that he serendipitously witnessed a monkey that would smoke cigarettes. A Fellowship at Mount Sinai Hospital in New York followed, where Murray became one of the pre-eminent researchers studying a newly discovered substance: LSD.

LSD research pivoted Murray into the emerging field of psychopharmacology in the mid-1950s and to a professorial position at the newly created Albert Einstein School of Medicine. It was here that Murray established himself as a premier researcher on effects of drugs on learning and behavior. 

Murray's interests in the mid-1960s turned toward tobacco smoking. Although Murray continued, initially, to study the effects of other drugs and memory, he eventually shifted his focus to smoking and nicotine addiction almost entirely.  

One of the first projects he attempted, spurred by the very memorable observation at Yerkes, was to attempt to get monkeys to smoke. This was partially successful and led to experiments with humans and rats so that by 1970 Murray had collected sufficient data to suggest that nicotine was key in the reinforcement of smoking. His work was included in subsequent Surgeon General Reports on smoking and nicotine addiction. 

Perhaps Murray Jarvik's most notable achievement was work done with Jed Rose in the 1980s investigating the possibility of delivering nicotine through the skin in sufficient quantities to affect smoking behavior. At first, their approach was quite simple, a basic poultice of nicotine. After much development, they were able to patent the concept of a nicotine transdermal patch, which they turned over to UCLA. It soon made it into production as the second FDA-approved pharmacologic treatment for smoking cessation after nicotine gum. With both established efficacy and ease of use, it was highly successful, for several years among the top three most profitable patents for the University of California.


By the 1960s, the emerging evidence of the danger of cigarette smoking was clear, but there was very little understanding of why people smoked. Cigarette smoking was generally thought of as a habit, with pharmacological factors receiving little or no attention.

Michael Russell was the man who did most to revolutionize our understanding. His research led to the 1988 report of the US Surgeon General, Nicotine Addiction, which finally brought recognition that cigarette smoking is a classic drug dependence.

Russell was a psychiatrist in training at the Maudsley Hospital, in south London, when he chose the topic of cigarette smoking for his research thesis in 1967. Based on his review of what was then fragmentary research literature, he concluded in a 1971 paper that the drug nicotine was the motivating force underlying smoking behavior. He made the study of the interacting pharmacological and psychological determinants of tobacco dependence his life's work.

Mike is regarded by many as the father of effective treatment to help smokers quit. But he is probably best known in the cessation field for a non-pharmacological intervention. In 1979 he published a trial examining the effectiveness of brief advice to quit smoking given by GPs in the course of routine consultations. The one-year success rate was 5%, compared with less than 1% in controls. A successful trial of nicotine chewing gum combined with brief advice in primary care followed. Mike Russell moved toward the concept of an integrated district smoking cessation service, in which routine delivery of advice and pharmacological therapy in primary care was combined with intensive clinic support. That vision has now been realized in Great Britain’s National Health Service.





The Fernö Award, named after Ove Fernö, honors scientists who have made groundbreaking advances in clinical research in one of three areas: (1) the pharmacological and behavioral actions of nicotine; (2) increased understanding on why people use tobacco; or (3) interventions to prevent tobacco use, to encourage or help tobacco users stop, and/or to reduce the adverse effects of tobacco use. 

2019 Award Recipient:

Caryn Lerman, PhD

Vice Dean for Strategic Initiatives, Perelmen School of Medicine
John H. Glick, M.D. Professor in Cancer Research
Department of Psychiatry, University of Pennsylvania
Philadelphia, Pennsylvania, USA


Ove Fernö was the inventor of nicotine replacement (NR). He was born in Gothenburg in 1916 and was trained as an organic chemist at the University of Lund, Lund, Sweden. During the late 1960s and 70s he was responsible for the development of the first NR product—a chewing gum. Tens of millions of smokers have used nicotine gum to aid their cessation attempts. In the United States, Dr. Murray Jarvik and Dr. Nina Schneider were the first to experiment with the gum; they became great ambassadors and conducted many important studies. The nicotine gum was first presented at the World Conference on Smoking and Health in New York in 1975.

Today, NR is marketed in some 70 countries. Ove Fernö´s thinking and foresight, and perhaps personal circumstances, made him a decisive driver in the development of Nicotine Replacement. His work has helped countless smokers to break the dependence. But he was also a great man to spend an evening with, usually over a glass of beer, to speculate about the future of NT and other matters of importance, very often philosophy.



Aleksandra Alcheva

Sabeeh Baig

Kai-Wen Cheng

Shannon S. Cigan

Adam Cole

Laurel Curry

Ghazaul Dezfuli

Katherine East

Noah Gubner

Marzena Hiler

Mirte Kuipers

Marin Kurti

Tzu Tsun Luk

Olusegun Owotomo

Rebecca Richmond

Kevin Schroth

Matthew Stone

Minoru Takeuchi

Soha Talih

Natalie Voos

Wei Xia



Priti Bandi

John Correa

Patricia Escobedo

Josephine Hinds

Asti Jackson

Dina  Jones

Stella Lee

Anuja Majmundar

Ahn Ngo

Raina Pang

Michael Ramsey

Ce Shang

Alayna Tackett


Connect With Us
Membership Management Software Powered by YourMembership  ::  Legal